"Oncocytoid Renal Cell Carcinomas After Neuroblastoma" Represent TSC -mutated Eosinophilic Solid and Cystic Renal Cell Carcinomas : Association With Prior Childhood Malignancy and Multifocality With Therapeutic Implications.
Journal
The American journal of surgical pathology
ISSN: 1532-0979
Titre abrégé: Am J Surg Pathol
Pays: United States
ID NLM: 7707904
Informations de publication
Date de publication:
01 12 2023
01 12 2023
Historique:
medline:
15
11
2023
pubmed:
31
7
2023
entrez:
31
7
2023
Statut:
ppublish
Résumé
The concept of oncocytoid renal cell carcinoma in patients who have survived neuroblastoma as a distinct biologic entity has been controversial since its original description in 1999. This is in part because similar oncocytoid renal cell carcinomas have been described in association with other pediatric cancers, and also because other renal cell carcinoma subtypes (such as MiT family translocation renal cell carcinoma) have been described in children who have survived neuroblastoma. We identified an index case of a child who survived medulloblastoma and developed multifocal bilateral oncocytoid renal cell carcinomas with morphology and immunophenotype compatible with eosinophilic solid and cystic renal cell carcinoma (ESC RCC) and demonstrated that both neoplasms harbored distinctive mutations in the TSC1/TSC2 genes. Remarkably, the child's remaining bilateral multifocal renal neoplasms completely responded to MTOR inhibitor therapy without need for further surgery. To confirm our hypothesis that oncocytoid renal cell carcinomas after childhood cancer represent ESC RCC, we obtained formalin-fixed paraffin-embedded tissue blocks from 2 previously published cases of oncocytoid renal cell carcinoma after neuroblastoma, confirmed that the morphology and immunophenotype was consistent with ESC RCC, and demonstrated that both cases harbored somatic TSC gene mutations. Both expressed markers previously associated with neoplasms harboring TSC gene mutations, glycoprotein nonmetastatic B, and cathepsin K. Of note, one of these patients had 2 ESC RCC which harbored distinctive TSC2 mutations, while the background kidney of the other patient had multiple small cysts lined by similar oncocytoid cells which showed loss of TSC2 protein. We then reviewed 3 of 4 cases from the original 1999 report of oncocytoid renal cell carcinomas after neuroblastoma, found that all 3 demonstrated morphology (including basophilic cytoplasmic stippling) that is characteristic of ESC RCC, showed that all 3 overexpressed glycoprotein nonmetastatic B, and showed that both cases with adequate material demonstrated loss of TSC2 protein and expressed cytokeratin 20 and cathepsin K by immunohistochemistry. In summary, "oncocytoid renal cell carcinomas after neuroblastoma" represent ESC RCC which are often multifocal in patients who have survived childhood cancer, likely representing an incompletely characterized tumor predisposition syndrome. MTOR-targeted therapy represents an effective therapeutic option for such patients to preserve functional nephrons.
Identifiants
pubmed: 37522346
doi: 10.1097/PAS.0000000000002101
pii: 00000478-990000000-00210
doi:
Substances chimiques
Cathepsin K
EC 3.4.22.38
Biomarkers, Tumor
0
Transcription Factors
0
TOR Serine-Threonine Kinases
EC 2.7.11.1
Glycoproteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1335-1348Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest and Source of Funding: Supported in part by: Dahan Translocation Carcinoma Fund (P.A.) and Joey’s Wings (P.A.). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.
Références
Medeiros LJ, Palmedo G, Krigman HR, et al. Oncocytoid renal cell carcinoma after neuroblastoma: a report of four cases of a distinct clinicopathologic entity. Am J Surg Pathol. 1999;23:772–780.
Medeiros LJ Eble JN, Sauter G, Epstein JI, et al. Renal cell carcinoma associated with neuroblastoma. World Health Organization Classification of Tumors Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs. IARC Press; 2004:39.
Argani P, Laé M, Ballard ET, et al. Translocation carcinomas of the kidney after chemotherapy in childhood. J Clin Oncol. 2006;24:1529–1534.
Dhall D, Al-Ahmadie HA, Dhall G, et al. Pediatric renal cell carcinoma with oncocytoid features occurring in a child after chemotherapy for cardiac leiomyosarcoma. Urology. 2007;70:178.e13–5.
Moch H, Amin MB, Argani P, et al. Moch H, Humphrey PA, Ulbright TM, Reuter VE. Renal cell tumors, Introduction. WHO Classification of Tumors of the Urinary System and Male Genital Organs, 4th Edition. IARC; 2016:16.
WHO Classification of Tumours Editorial Board. Urinary and Male Genital Tumors, 5th Edition. International Agency for Research on Cancer; 2022.
Trpkov K, Hes O, Bonert M, et al. Eosinophilic, solid, and cystic renal cell carcinoma. Clinicopathologic study of 16 unique, sporadic neoplasms occurring in women. Am J Surg Pathol. 2016;40:60–71.
Falzarano SM, McKenney JK, Montironi R, et al. Renal cell carcinoma occurring in patients with prior neuroblastoma: a heterogenous group of neoplasms. Am J Surg Pathol. 2016;40:989–997.
Palsgrove DN, Li Y, Pratilas CA, et al. Eosinophilic solid and cystic (ESC) renal cell carcinomas harbor TSC mutations: molecular analysis supports an expanding clinicopathologic spectrum. Am J Surg Pathol. 2018;42:1166–1181.
Mehra R, Vats P, Cao X, et al. Somatic Bi-allelic loss of TSC genes in eosinophilic solid and cystic renal cell carcinoma. Eur Urol. 2018;74:483–486.
Parilla M, Kadri S, Patil S, et al. Are sporadic eosinophilic solid and cystic renal cell carcinomas characterized by somatic tuberous sclerosis gene mutations. Am J Surg Pathol. 2018;42:911–917.
Gondek L, Zheng G, Ghiaur G, et al. Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation. Leukemia. 2016;30:1916–1920.
Argani P, Reuter VE, Eble JN, et al. Biphasic hyalinizing psammomatous renal cell carcinoma (BHP RCC): a distinctive neoplasm associated with somatic NF2 mutations. Am J Surg Pathol. 2020;44:901–916.
Li MM, Datto M, Duncavage EJ, et al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: a Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017;19:4–23.
Smith NE, Illei PB, Allaf M, et al. t(6;11) renal cell carcinoma (RCC): expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases. Am J Surg Pathol. 2014;38:604–614.
Salles DC, Asrani K, Woo J, et al. GPNMB expression identifies TSC1/2/mTOR-associated and translocation-driven renal tumors. J Pathol. 2022;257:158–171.
Yamamoto T, Pipo JR, Feng JH, et al. Novel TSC1 and TSC2 mutations in Japanese patients with tuberous sclerosis complex. Brain Dev. 2002;24:227–230.
van Eeghen AM, Nellist M, van Eeghen EE, et al. Central TSC2 missense mutations are associated with a reduced risk of infantile spasms. Epilepsy Res. 2013;103:83–87.
Feng JH, Ding MP, Yang CW. Analysis of gene mutation in patients with tuberous sclerosis complex with polymerase chain reaction-single strand conformation polymorphism. Zhonghua Er Ke Za Zhi. 2003;41:223–226.
Altarescu G, Beeri R, Eldar-Geva T, et al. PGD for germline mosaicism. Reprod Biomed Online. 2012;25:390–395.
Zhang R, Wang J, Wang Q, et al. Identification of a novel TSC2 c.3610G > A, p.G1204R mutation contribute to aberrant splicing in a patient with classical tuberous sclerosis complex: a case report. BMC Med Genet. 2018;19:173.
Dabora SL, Jozwiak S, Franz DN, et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet. 2001;68:64–80.
Franz DN, Brody A, Meyer C, et al. Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med. 2001;15:661–668.
Hoogeveen-Westerveld M, Ekong R, Povey S, et al. Functional assessment of TSC2 variants identified in individuals with tuberous sclerosis complex. Hum Mutat. 2013;34:167–175.
Hodges AK, Li S, Maynard J, et al. Pathological mutations in TSC1 and TSC2 disrupt the interaction between hamartin and tuberin. Hum Mol Genet. 2001;1:2899–2905.
Kwiatkowski DJ, Palmer MR, Jozwiak S, et al. Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2. Eur J Hum Genet. 2015;23:1665–1672.
Martignoni G, Gobbo S, Camparo P, et al. Differential expression of cathepsin-K in neoplasms harbouring TFE3 gene fusions. Mod Pathol. 2011;24:1313–1319.
Li Y, Reuter VE, Matoso A, et al. Re-evaluation of 33 ‘unclassified’ eosinophilic renal cell carcinomas in young patients. Histopathology. 2018;72:588–600.
Tyburczy ME, Dies KA, Glass J, et al. Mosaic and intronic mutations in TSC1/TSC2 explain the majority of tsc patients with no mutation identified by conventional testing. PLoS Genet. 2015;5:1–17.
Qin W, Kozlowski P, Taillon BE, et al. Ultra deep sequencing detects a low rate of mosaic mutations in tuberous sclerosis complex. Hum Genet. 2010;127:573–582.
Treichel AM, Boeszoermenyi B, Lee CR, et al. Diagnosis of mosaic tuberous sclerosis complex using next-generation sequencing of subtle or unusual cutaneous findings. JID Innov. 2023;9:1–6.
Moodalbail DG, Apple LZ, Meyers KE, et al. Acquired multiple cysts of the kidney in neuroblastoma survivors. Am J Kidney Dis. 2016;68:134–137.
Chen YB, Mirsadraei L, Jayakumaran G, et al. Somatic mutations of TSC2 or MTOR characterize a morphologically distinct subset of sporadic renal cell carcinoma with eosinophilic and vacuolated cytoplasm. Am J Surg Pathol. 2019;43:121–131.
Trpkov K, Hes O, Williamson SR, et al. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Mod Pathol. 2021;34:1392–1424.
Trpkov K, Williamson SR, Gao Y, et al. Low-grade oncocytic tumour of kidney (CD117-negative, cytokeratin 7 positive): a distinct entity? Histopathology. 2019;75:174–184.
McKenney JK, Przybycin CG, Trpkov K, et al. Eosinophilic solid and cystic renal cell carcinomas have metastatic potential. Histopathology. 2018;72:1066–1067.
Murphy AJ, Davidoff AM. Nephron-sparing surgery for Wilms tumor. Front Pediatr. 2023;11:1122390.
Argani P, Matoso A, Pallavajjalla A, et al. Xanthomatous giant cell renal cell carcinoma: another morphologic form of TSC-associated renal cell carcinoma. Am J Surg Pathol. 2022;46:1554–1561.
Xia QY, Wang XT, Zhao M, et al. TSC/MTOR-associated eosinophilic renal tumors exhibit a heterogeneous clinicopathologic spectrum : a targeted next-generation sequencing and gene expression profiling study. Am J Surg Pathol. 2022;46:1562–1576.
Kwiatkowski DJ, Choueiri TK, Fay AP, et al. Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2016;22:2445–2452.